Today, the CEO of Second Sight Medical Products (NASDAQ: EYES), Jonathan Will McGuire, bought shares of EYES for $6,043.
Following this transaction Jonathan Will McGuire’s holding in the company was increased by 3.37% to a total of $187.6K. In addition to Jonathan Will McGuire, one other EYES executive reported Buy trades in the last month.
See today’s analyst top recommended stocks >>
Currently, Second Sight Medical Products has an average volume of 135K. The Company has a Price to Book ratio of 16.6052.
Starting in July 2015, EYES received 16 Buy ratings in a row.
The insider sentiment on Second Sight Medical Products has been positive according to 40 insider trades in the past three months. This sentiment is slightly higher than the average sentiment of company insiders in this sector.
Company insider trades’ information is brought to you by the DailyInsider, a proprietary algorithm that analyzes insider trading activity to detect the most attractive trading opportunities. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Second Sight Medical Products, Inc. develops, manufactures and markets prosthetic devices. Its product the Argus II System, treats outer retinal degenerations and employs electrical stimulation to bypass degenerated photoreceptor cells and to stimulate remaining viable retinal cells thereby inducing visual perception in blind individuals.
